ZWZiyang Wu

Ziyang Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ziyang Wu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaohui Xie

    Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China

    2 shared publications
  • Xin Du

    Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical Sciences Peking University Beijing China

    2 shared publications
  • Yibo Wu

    Department of Nursing, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China

    2 shared publications
  • Chenrong Huang

    Department of Pharmacy The First Affiliated Hospital of Soochow University Suzhou Jiangsu China

    1 shared publication
  • Cong Huang

    Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical Sciences Peking University Beijing China

    1 shared publication
  • Jiameng Xie

    College of Pharmaceutical Science Soochow University Suzhou Jiangsu China

    1 shared publication

Latest Publications

  • Open Access

    Patient‐derived tumor organoids exhibit high predictive accuracy and clinical promise across cancers: A systematic review and meta‐analysis

    by Sijia Li, Jiameng Xie, Ziyang Wu, Liyan Miao, Chenrong Huang

    Patient‐derived tumor organoids (PDTOs) have emerged as a promising functional platform for precision oncology, yet their clinical translation remains constrained by heterogeneous evidence and insufficient methodological standardization. This study systematically reviewed the clinical utility and limitations of PDTO‐based drug sensitivity testing across different cancer types and treatment settings. PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov were searched from inception to June 18, 2026, and studies or registered clinical trials evaluating associations between PDTO drug sensitivity and clinical outcomes were included. A total of 54 studies and 97 registered clinical trials involving 17 cancer types were identified. The establishment success rates of PDTOs ranged from 31.25% to 100.00%, and drug sensitivity was predominantly evaluated using cell viability assays, although response thresholds varied considerably across studies. Quantitative synthesis of 31 studies showed that PDTO‐based drug sensitivity testing achieved a pooled sensitivity of 0.91 (95% CI, 0.83–0.95), specificity of 0.79 (95% CI, 0.65–0.88), and SROC AUC of 0.93 (95% CI, 0.90–0.95) for predicting treatment response. Concordance between PDTO predictions and clinical responses ranged from 53.33% to 100.00%, and PDTO sensitivity appeared to be associated with long‐term survival outcomes. Registered clinical trials encompassed 21 cancer types and were mainly observational, with most studies still ongoing. Overall, PDTOs show considerable potential as a functional drug sensitivity testing approach for predicting treatment response and guiding personalized therapy selection. However, further prospective validation, harmonization of methodologies, and standardized evaluation criteria are required before their widespread implementation in precision oncology.

  • Open Access

    The impact of smoking status on the progression‐free survival of non‐small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta‐analysis

    by Xinyi Li, Cong Huang, Xiaohui Xie, Ziyang Wu, Xia Tian, Yibo Wu, Xin Du, Luwen Shi

    What is known and Objective Smoking has a notable influence on the efficacy of medications for lung cancer. Previous studies illustrated the correlation between smoking and the efficacy of first‐line Epidermal Growth Factor Receptors‐Tyrosine Kinase Inhibitors (EGFR‐TKIs). The benefit of smokers in immunotherapy was still controversial. Here, we investigated the impact of smoking on clinical outcomes of molecularly targeted therapies or immunotherapy in Non‐Small Cell Lung Cancer (NSCLC). Methods We performed meta‐analysis including trials comparing EGFR‐TKIs, Anaplastic Lymphoma Kinase (ALK) inhibitors or Immune Checkpoint Inhibitors (ICIs) against chemotherapy in NSCLC. The Progression‐Free Survival (PFS)‐Hazard Ratios (HRs) of two groups served as the index and we used random effects to pool outcomes. Results and discussion Twenty randomized trials were selected. Compared with chemotherapy, treatment with EGFR‐TKIs had similar benefit in never‐smokers (PFS: HR = 0.46, 95% CI 0.30 to 0.69) and smokers (PFS: HR = 0.68, 95% CI 0.50 to 0.91; p = 0.135) while non‐smokers (PFS: HR = 0.32, 95% CI 0.23 to 0.44) had better benefit from first‐line EGFR‐TKIs than smokers (PFS: HR = 0.54, 95% CI 0.41 to 0.71; p = 0.02). Treatment with ALK inhibitors had similar benefits in never‐smokers (PFS: HR = 0.43, 95% CI 0.35 to 0.53) and smokers (PFS: HR = 0.56, 95% CI 0.44 to 0.71; p = 0.406). The benefit of ICIs in smokers (PFS: HR = 0.79, 95% CI 0.64 to 0.98) was significantly greater than never‐smokers (PFS: HR = 1.81, 95% CI 1.27 to 2.57; p = 0.004). What is new and Conclusion Smoking status is an important clinical predictor of therapy in NSCLC. Never‐smokers and smokers have similar benefit with EGFR‐TKIs therapy compared with chemotherapy, while never‐smokers have greater benefit after first‐line EGFR‐TKIs therapy. There was similar benefit in never‐smokers and smokers when using ALK inhibitors over chemotherapy. Additionally, ICIs treatment over chemotherapy leads to more favourable PFS in smokers both in first‐line and second‐line settings.


  • Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non–small‐cell lung cancer patients: A network meta‐analysis

    by Ziyang Wu, Suhua Chen, Xin Du, Yibo Wu, Xiaohui Xie

    What is known and objective The efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) in patients diagnosed with non–small‐cell lung cancer (NSCLC) has been confirmed by a large number of studies. However, hepatotoxicity caused by EGFR‐TKIs has not been widely investigated. This review compares the hepatotoxicity of different EGFR‐TKIs through a network meta‐analysis. Methods PubMed, EMBASE, Cochrane Library and ClinicalTrials.gov were systematically searched from their individual inceptions to 20 May 2020 with the goal of identifying randomized controlled trials (RCTs) reporting hepatotoxicity in NSCLC patients receiving EGFR‐TKIs. A random‐effects pairwise meta‐analysis and network meta‐analysis were performed within a frequentist framework. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated. Results Twelve eligible RCTs, including data from 6,280 patients diagnosed with NSCLC, were analysed. In our network meta‐analysis, gefitinib was associated with a higher risk for hepatotoxicity compared to placebo (RR, 2.55; 95% CI, 1.32‐4.89) and dacomitinib (RR, 2.60; 95% CI, 1.30‐5.20) in terms of all‐grades alanine transaminase (ALT) elevation. As for all‐grades aspartate transaminase (AST) elevation, gefitinib and erlotinib showed a significantly increased risk for hepatotoxicity compared to afatinib, dacomitinib and placebo (erlotinib vs. afatinib: RR, 1.85; 95% CI, 1.05‐3.24; erlotinib vs. dacomitinib: RR, 1.68; 95% CI, 1.19‐2.36; erlotinib vs. placebo: RR, 3.38; 95% CI, 1.69‐6.73; gefitinib vs. afatinib: RR, 2.23; 95% CI, 1.32‐3.79; gefitinib vs. dacomitinib: RR, 2.03; 95% CI, 1.51‐2.73; gefitinib vs. placebo: RR, 4.08; 95% CI, 2.11‐7.91). There was a high risk of high‐grade ALT elevation in patients treated with gefitinib compared to patients treated with erlotinib (RR, 4.31; 95% CI, 2.15‐8.66), dacomitinib (RR, 6.95; 95% CI, 1.85‐26.05) or placebo (RR, 8.38; 95% CI, 1.56‐45.01). No statistically significant differences were identified among the five agents analysed in terms of all‐grades TB elevation and high‐grade AST elevation. The surface under the cumulative ranking curve (SUCRA) revealed that gefitinib showed a potentially higher risk for ALT and AST elevation compared to other EGFR‐TKIs regardless of grade. What is new and conclusion Current evidence indicates that the association between afatinib or dacomitinib and risk of liver enzyme elevation remains uncertain in patients diagnosed with NSCLC. Some evidence suggests that gefitinib and erlotinib may be associated with a significantly increased risk for hepatotoxicity in patients with NSCLC. However, given that the elevation of liver enzymes was not definitely associated with EGFR‐TKIs and publication bias, further studies are required to confirm these results.